Fresenius Medical Care Achieves Extraordinary Earnings Growth and Looks Ahead to a Brighter Future Fresenius Medical Care reported exceptional earnings growth in 2025, with a 27% increase in operating income, surpassing financial forecasts and setting the stage for future expansion.

Fresenius Medical Care Achieves Extraordinary Earnings Growth and Looks Ahead to a Brighter Future #Germany #Fresenius_Medical_Care #Bad_Homburg #5008X_CAREsystem #FME25+_Program

Fresenius Medical Care Boosts EUR 1 Billion Buyback Program with Rapid Execution Fresenius Medical Care accelerates its EUR 1 billion share buyback program, committing to repurchase nearly EUR 415 million worth of shares within months.

Fresenius Medical Care Boosts EUR 1 Billion Buyback Program with Rapid Execution #Germany #share_buyback #Fresenius_Medical_Care #Bad_Homburg #Fresenius

Fresenius Medical Care Welcomes Charles Hugh-Jones as New Global Chief Medical Officer Fresenius Medical Care has appointed Charles Hugh-Jones as Global Chief Medical Officer starting January 1, 2026, replacing Franklin W. Maddux.

Fresenius Medical Care Welcomes Charles Hugh-Jones as New Global Chief Medical Officer #Germany #Fresenius_Medical_Care #Bad_Homburg #Charles_Hugh-Jones #Franklin_Maddux

Fresenius Medical Care Reports Strong Revenue and Earnings Growth in Q3 2025 Fresenius Medical Care showcases robust organic revenue growth and significant operating income increase in Q3 2025, indicating strong financial performance.

Fresenius Medical Care Reports Strong Revenue and Earnings Growth in Q3 2025 #Germany #Q3_2025 #Fresenius_Medical_Care #Bad_Homburg #Earnings_Growth

Fresenius Medical Care Showcases Innovations in Hemodiafiltration and AI at ASN Kidney Week 2025 Fresenius Medical Care will present groundbreaking research on hemodiafiltration and artificial intelligence at the ASN Kidney Week 2025, focusing on improving patient outcomes.

Fresenius Medical Care Showcases Innovations in Hemodiafiltration and AI at ASN Kidney Week 2025 #Germany #AI_in_Healthcare #Fresenius_Medical_Care #Bad_Homburg #Hemodiafiltration

Joseph Turk Named New CEO of Fresenius Medical Care's Care Enablement Division Fresenius Medical Care has appointed Joseph Turk as the new CEO of its Care Enablement segment, effective January 1, 2026, succeeding Dr. Katarzyna Mazur-Hofsäß.

Joseph Turk Named New CEO of Fresenius Medical Care's Care Enablement Division #Germany #Fresenius_Medical_Care #Bad_Homburg #Joseph_Turk #Care_Enablement

Fresenius Medical Care Expands Value-Based Care Strategy with Key Investments and Leadership Changes Fresenius Medical Care enhances its Value-Based Care strategy by investing in Interwell Health and appointing a new CEO, highlighting innovation in kidney care.

Fresenius Medical Care Expands Value-Based Care Strategy with Key Investments and Leadership Changes #Germany #Interwell_Health #Value-Based_Care #Fresenius_Medical_Care #Bad_Homburg

Fresenius Medical Care Launches Significant Share Buyback Program to Enhance Shareholder Value Fresenius Medical Care announces the initiation of a EUR 600 million share buyback program as part of its commitment to boost shareholder value and support its new strategic framework.

Fresenius Medical Care Launches Significant Share Buyback Program to Enhance Shareholder Value #Germany #share_buyback #investment_strategy #Fresenius_Medical_Care #Bad_Homburg

Fresenius Medical Care Reports Strong Revenue and Income Growth in Q2 2025 Fresenius Medical Care showcases robust organic revenue growth of 7% and impressive operating income advancement in Q2 2025, reaffirming its financial outlook.

Fresenius Medical Care Reports Strong Revenue and Income Growth in Q2 2025 #Germany #Financial_Growth #Q2_2025 #Bad_Homburg #Fresenius_Medical

Frenova and Nephronomics Unite to Elevate Kidney Disease Treatment with Genomics Innovation Fresenius Medical Care's Frenova collaborates with Nephronomics and GENEWIZ to enhance genomic analysis, aiming for breakthroughs in precision kidney disease care.

Frenova and Nephronomics Unite to Elevate Kidney Disease Treatment with Genomics Innovation #Germany #Bad_Homburg #Fresenius #Frenova #Nephronomics

Fresenius Medical Care Unveils FME Reignite Strategy for Kidney Care Excellence and Profitability Fresenius Medical Care introduces its FME Reignite strategy aimed at setting new standards for kidney care while enhancing profitability and shareholder returns.

Fresenius Medical Care Unveils FME Reignite Strategy for Kidney Care Excellence and Profitability #Germany #Fresenius_Medical_Care #Bad_Homburg #FME_Reignite #5008X_machine

Fresenius Medical Care Initiates Expanded U.S. Rollout of 5008X™ CAREsystem for Kidney Disease Treatment Fresenius Medical Care has achieved FDA clearance for the updated 5008X CAREsystem to enhance hemodiafiltration therapy across the U.S., marking a key milestone in kidney care.

Fresenius Medical Care Initiates Expanded U.S. Rollout of 5008X™ CAREsystem for Kidney Disease Treatment #USA #Fresenius_Medical_Care #Bad_Homburg #5008X_CAREsystem #Hemodiafiltration

Fresenius Medical Care Unveils Innovative Research for Kidney Care at ERA 2025 Discover Fresenius Medical Care's groundbreaking research for kidney care presented at ERA 2025, showcasing AI advancements and improved patient outcomes.

Fresenius Medical Care Unveils Innovative Research for Kidney Care at ERA 2025 #Germany #Kidney_Care #Bad_Homburg #Fresenius_Medical #ERA_Congress

Fresenius Medical Care's AGM Sets Record Dividend Amid Strong Growth and Transformation Fresenius Medical Care's shareholders approve a historic dividend of 1.44 Euros per share, marking a significant year-over-year increase amid impressive financial growth.

Fresenius Medical Care's AGM Sets Record Dividend Amid Strong Growth and Transformation #Germany #Dividend #Kidney_Care #Fresenius_Medical_Care #Bad_Homburg

Fresenius Medical Care Achieves Notable Growth in First Quarter 2025, Showcasing Operational Success Fresenius Medical Care has demonstrated strong organic revenue and income growth in Q1 2025, continuing its strategic plan with impressive operational success.

Fresenius Medical Care Achieves Notable Growth in First Quarter 2025, Showcasing Operational Success #Germany #Fresenius_Medical_Care #Bad_Homburg #Earnings_Growth #renal_disease

Fresenius Medical Care Reports Impressive 18% Earnings Growth for 2024 and Eyes Further Acceleration in 2025 Fresenius Medical Care has showcased remarkable earnings growth and an optimistic outlook for 2025, highlighting its strategies in care delivery and operational efficiency.

Fresenius Medical Care Reports Impressive 18% Earnings Growth for 2024 and Eyes Further Acceleration in 2025 #Germany #Fresenius_Medical_Care #Bad_Homburg #Earnings_Growth #Care_Delivery

Fresenius Medical Care Completes Strategic Sale to Quest Diagnostics For Enhanced Dialysis Services Fresenius Medical Care announces the sale of select laboratory assets to Quest Diagnostics, enhancing dialysis-related services across the U.S.

Fresenius Medical Care Completes Strategic Sale to Quest Diagnostics For Enhanced Dialysis Services #Germany #Quest_Diagnostics #Fresenius_Medical_Care #Bad_Homburg #Dialysis_Services

Fresenius Medical Care Achieves Ranking in Dow Jones Sustainability Index for 15th Consecutive Year Fresenius Medical Care continues to excel in sustainability, marked by its inclusion in the Dow Jones Sustainability Index and significant environmental achievements.

Fresenius Medical Care Achieves Ranking in Dow Jones Sustainability Index for 15th Consecutive Year #Germany #Fresenius_Medical_Care #Bad_Homburg #Dow_Jones_Sustainability #Environmental_Leadership

Fresenius Medical Care Rejoins the DAX 40 Index: A Testament to Their Dedication and Growth Fresenius Medical Care is set to return to Germany's DAX 40 Index on December 27, 2024, marking a significant achievement and recognition of their dedication in serving patients with kidney disease.

Fresenius Medical Care Rejoins the DAX 40 Index: A Testament to Their Dedication and Growth #Germany #kidney_disease #Fresenius_Medical_Care #DAX_40 #Bad_Homburg